Dual citizenship at the Ebola virus disease bedside: notes from a steep learning curve.

Join us for a special lecture by our guest speaker Ian Crozier:

A steep (but challenging) learning curve over the last decade has provided new insight toward improving outcomes at the Ebola virus disease bedside, including in acute and post-acute settings. In the context of historical challenges, recent progress and outstanding research questions will be discussed through trifocal lenses (as clinician, patient, and scientist).

Programme:

• 2:30pm: Introduction

• 2:45pm: Lecture

• 3:45pm: Reception

• 4:45pm: End

Speaker: Ian Crozier

Title: Dual citizenship at the Ebola virus disease bedside - notes from a steep learning curve

Register: Please register to attend in person or to follow online

Short Bio:
Ian Crozier is an infectious diseases clinician-scientist at the Frederick National Lab providing chief medical officer support to NIH/NIAID’s Integrated Research Facility (IRF) at Fort Detrick. His position enables bidirectional agility between the Biosafety Level-4 (BSL-4) animal models of high consequence and emerging viral pathogens and the human outbreak disease bedside. At the cageside, current work focuses on animal model development for filoviral diseases, Lassa Fever, and SARS-CoV-2/COVID-19, including the use of medical imaging and deep learning to understand and characterize the host-pathogen interaction. At the clinical bedside, primarily in clinical and research efforts in Western and Central Africa, current focus is on improving acute (and post-acute) outcomes in filovirus disease(s) and on optimizing the clinical management of mpox as part of the ongoing PALM007 clinical trial of tecovirimat in the Democratic Republic of the Congo. He is originally from Bulawayo, Zimbabwe and completed his infectious diseases and medical training at Vanderbilt University. In a prior life, he spent many years based at the Infectious Diseases Institute (Kampala, Uganda) training African clinicians in complex decision-making in patients with HIV/AIDS, tuberculosis, and other common tropical infectious diseases. Research interests are informed both by extensive clinical experience and a prior personal experience of EVD that included critical illness and severe sequelae. Prior to coming to NIH, his work (with the World Health Organization and an Emory University Eye team) focused on acute EVD and then EVD survivors, targeting their clinical care needs, the management of residual risk related to viral persistence, and scientific questions newly emerging at EVD survivor bedsides.